Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Growth hormone axis · Compound

CJC-1295 (No DAC)

Mod GRF 1-29, a short-acting growth hormone-releasing hormone analogue without the albumin-binding DAC group.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 20264 min read

CJC-1295 (No DAC) is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does.

What is CJC-1295 (No DAC)

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a truncated, modified form of growth hormone-releasing hormone (GHRH). Unlike CJC-1295 with DAC, it lacks the group that binds albumin in the blood, so it is shorter-acting. Browse the full peptide library for related compounds.

The human trials of CJC-1295 in the evidence dataset this site draws on studied the DAC form, not this one. This page cites no primary study of the no-DAC form, so it makes no claim about its effects.

Ipamorelin, which acts on the ghrelin (growth hormone secretagogue) receptor, and tesamorelin, another growth hormone-releasing hormone analogue, have their own pages.

How it works

GHRH receptor (proposed): as a GHRH analogue, it is designed to act on the GHRH receptor in the pituitary, which signals growth hormone release. This page cites no study that measured it for the no-DAC form.

No albumin binding: without the DAC group it does not bind albumin, the modification that gives the DAC form a half-life of several days. The no-DAC form is therefore shorter-acting.

Benefits studied

CJC-1295 (No DAC) is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only.

Side effects reported

No controlled human data on adverse events for CJC-1295 (No DAC) is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial.

  • Water retention
  • Tingling in hands or feet
  • Increased hunger
  • Headache
  • Hypoglycemia
  • Pituitary desensitization (theoretical)

Regulatory status

The regulatory dataset this site draws on has no row for CJC-1295 (No DAC).

Who should not use CJC-1295 (No DAC)

FAQ

What is the difference between CJC-1295 with and without DAC?

CJC-1295 with DAC carries a reactive group that binds albumin in the blood, which extends its half-life to several days. The no-DAC form, Mod GRF 1-29, lacks that group and is shorter-acting. The human trials in the evidence dataset studied the DAC form.

What evidence exists for CJC-1295 without DAC?

The evidence dataset this site draws on maps its CJC-1295 human trials to the DAC form only. This page cites no primary study of the no-DAC form, so no benefit or trial figure is shown here.

Is CJC-1295 without DAC registered in the Philippines?

The regulatory dataset this site draws on has no separate row for the no-DAC form, so this page makes no claim about its registration status. The regulatory status page lists the compounds that dataset covers.

Where to get CJC-1295 (No DAC) in the Philippines

If the reading is done and the next step is a plan rather than another article, you can build a protocol around your goal at Longevity Manila, which hands off to our partner and supplier, Primara Labs.

The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.

View Supply Index

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 24, 2026

Related peptides

Updated